For example, BRCA2 alterations have been associated with platinum sensitivity in prostate and ovarian cancers, and mismatch repair gene variants (MSH2, MSH6) are relevant to immunotherapy responses in other tumor types. This evidence concerns the gene MSH2 and neoplasm.